Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis

Abstract Background Sertoli-Leydig cell tumors (SLCTs) are a rare group of sex cord-stromal tumors that account for less than 0.5% of all ovarian tumors. This study aims to compare the pathological and clinical characteristics of SLCTs with and without DICER1 hotspot mutations, highlighting the impa...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhuoyao Lyu, Yilin Liu, Jingci Chen, Pengyan Wang, Zhaohui Lu, Xiaoyan Chang, Xianlong Chen, Heng Ma, Shengwei Mo, Shuangni Yu, Jie Chen
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Diagnostic Pathology
Subjects:
Online Access:https://doi.org/10.1186/s13000-025-01657-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850042828078448640
author Zhuoyao Lyu
Yilin Liu
Jingci Chen
Pengyan Wang
Zhaohui Lu
Xiaoyan Chang
Xianlong Chen
Heng Ma
Shengwei Mo
Shuangni Yu
Jie Chen
author_facet Zhuoyao Lyu
Yilin Liu
Jingci Chen
Pengyan Wang
Zhaohui Lu
Xiaoyan Chang
Xianlong Chen
Heng Ma
Shengwei Mo
Shuangni Yu
Jie Chen
author_sort Zhuoyao Lyu
collection DOAJ
description Abstract Background Sertoli-Leydig cell tumors (SLCTs) are a rare group of sex cord-stromal tumors that account for less than 0.5% of all ovarian tumors. This study aims to compare the pathological and clinical characteristics of SLCTs with and without DICER1 hotspot mutations, highlighting the impact of these genetic variations on clinical manifestation, prognosis, and pathological morphology. Methods A retrospective analysis was conducted on 50 SLCTs. DICER1 RNase IIIb hotspot mutations were detected by the Sanger sequence. Clinical information, such as patients' symptoms, tumor staging, prognosis, and pathological features, such as tumor differentiation and growth patterns, were collected. Results DICER1 mutation only appears in the intermediate/poorly differentiated SLCTs (35.7%), while none in the well-differentiated SLCTs. The patients with DICER1 mutation had a younger age of onset (17, 15–25) compared to the wild-type group (42, 27–58). Regarding pathological morphology, the mutant group showed a higher probability of having retiform components (40.0%) and cords or ribbon-like arrangement (33.3%). Besides, they exhibited mucinous edematous stroma (80.0%) and hemorrhage (80.0%) more frequently than the wild-type group. The mutant tumor had more mitotic figures. (11/10HPF), higher Ki-67 index (16.1%), and more CD20-positive cell infiltration. Patients of the mutant group were more likely to experience recurrence, and their tumors were more prone to rupture. Conclusions This study demonstrates that DICER1-mutant and wildtype SLCTs have marked differences in pathological morphology and clinical manifestation. DICER1-mutatant SLCTs display worse prognosis, higher proliferative activity, and potentially more active immune microenvironments, which underscores the importance of genetic testing in diagnosing and assessing the prognosis of SLCTs.
format Article
id doaj-art-308fefe84da24e558d57309bca3cad9e
institution DOAJ
issn 1746-1596
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series Diagnostic Pathology
spelling doaj-art-308fefe84da24e558d57309bca3cad9e2025-08-20T02:55:25ZengBMCDiagnostic Pathology1746-15962025-04-012011910.1186/s13000-025-01657-8Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysisZhuoyao Lyu0Yilin Liu1Jingci Chen2Pengyan Wang3Zhaohui Lu4Xiaoyan Chang5Xianlong Chen6Heng Ma7Shengwei Mo8Shuangni Yu9Jie Chen10Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Sertoli-Leydig cell tumors (SLCTs) are a rare group of sex cord-stromal tumors that account for less than 0.5% of all ovarian tumors. This study aims to compare the pathological and clinical characteristics of SLCTs with and without DICER1 hotspot mutations, highlighting the impact of these genetic variations on clinical manifestation, prognosis, and pathological morphology. Methods A retrospective analysis was conducted on 50 SLCTs. DICER1 RNase IIIb hotspot mutations were detected by the Sanger sequence. Clinical information, such as patients' symptoms, tumor staging, prognosis, and pathological features, such as tumor differentiation and growth patterns, were collected. Results DICER1 mutation only appears in the intermediate/poorly differentiated SLCTs (35.7%), while none in the well-differentiated SLCTs. The patients with DICER1 mutation had a younger age of onset (17, 15–25) compared to the wild-type group (42, 27–58). Regarding pathological morphology, the mutant group showed a higher probability of having retiform components (40.0%) and cords or ribbon-like arrangement (33.3%). Besides, they exhibited mucinous edematous stroma (80.0%) and hemorrhage (80.0%) more frequently than the wild-type group. The mutant tumor had more mitotic figures. (11/10HPF), higher Ki-67 index (16.1%), and more CD20-positive cell infiltration. Patients of the mutant group were more likely to experience recurrence, and their tumors were more prone to rupture. Conclusions This study demonstrates that DICER1-mutant and wildtype SLCTs have marked differences in pathological morphology and clinical manifestation. DICER1-mutatant SLCTs display worse prognosis, higher proliferative activity, and potentially more active immune microenvironments, which underscores the importance of genetic testing in diagnosing and assessing the prognosis of SLCTs.https://doi.org/10.1186/s13000-025-01657-8Sertoli-Leydig cell tumorsDICER1RNase IIIb hotspot mutationsClinical featuresPathological characteristics
spellingShingle Zhuoyao Lyu
Yilin Liu
Jingci Chen
Pengyan Wang
Zhaohui Lu
Xiaoyan Chang
Xianlong Chen
Heng Ma
Shengwei Mo
Shuangni Yu
Jie Chen
Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
Diagnostic Pathology
Sertoli-Leydig cell tumors
DICER1
RNase IIIb hotspot mutations
Clinical features
Pathological characteristics
title Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
title_full Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
title_fullStr Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
title_full_unstemmed Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
title_short Pathological and clinical insights into DICER1 hotspot mutated Sertoli-Leydig cell tumors: a comparative analysis
title_sort pathological and clinical insights into dicer1 hotspot mutated sertoli leydig cell tumors a comparative analysis
topic Sertoli-Leydig cell tumors
DICER1
RNase IIIb hotspot mutations
Clinical features
Pathological characteristics
url https://doi.org/10.1186/s13000-025-01657-8
work_keys_str_mv AT zhuoyaolyu pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT yilinliu pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT jingcichen pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT pengyanwang pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT zhaohuilu pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT xiaoyanchang pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT xianlongchen pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT hengma pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT shengweimo pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT shuangniyu pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis
AT jiechen pathologicalandclinicalinsightsintodicer1hotspotmutatedsertolileydigcelltumorsacomparativeanalysis